Close

TESARO (TSRO) Receives FDA CRL for Rolapitant IV NDA

January 12, 2017 6:01 AM EST Send to a Friend
TESARO, Inc. (NASDAQ: TSRO) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login